1. Scrip

With Vuity Approval, AbbVie Continues Stepping Into Eye Care

Presbyopia Drug Carries On Allergan Legacy

 
• By Joseph Haas

AbbVie had no presence in ophthalmic medicine other than a single indication for Humira before the Allergan merger, but now has a growing eye care portfolio, including early FDA approval of Vuity for presbyopia.

Eye in an high tech environment
AbbVie has more ophthalmology plans beyond first eye drop approval for presbyopia

Eye care was barely a blip on the radar at AbbVie Inc. when it acquired Allergan plc – a 2016 label expansion of top-seller Humira (adalimumab) into uveitis was AbbVie’s only foray into ophthalmic medicine before the mega-merger that happened to bring it into the sector. Eye care R&D and product performance still may not be a central topic during AbbVie’s quarterly earnings calls, but the recent approval of Vuity for presbyopia represents progress for the combined company’s burgeoning eye care segment.

During its third quarter earnings call on 29 October, AbbVie noted that its eye care franchise – led by dry...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

What Incyte Investors Expect From New CEO Bill Meury

 
• By Andrew McConaghie

Fresh from having sold Anthos to Novartis, the new CEO is expected to update the oncology and dermatology-focused firm's strategy.

Bayer Buoyant After EU Nod For Twice-Yearly Eylea

 
• By Kevin Grogan

Green light follows a recent rejection by the US FDA to partner Regeneron's request for an extension to the dosing interval.

Executives On The Move: New CEO At Atalanta Therapeutics

Recent moves in the industry include C-suite changes at Atalanta Therapeutics and Climb Bio, plus seven companies get new CMOs.